Rapport Therapeutics (RAPP) Net Cash Flow (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Net Cash Flow of $25.4 million for Q1 2026, up 3080.35% year-over-year from $799000.0 in Q1 2025, and up 112.79% quarter-over-quarter from -$198.7 million in Q4 2025.
Rapport Therapeutics (RAPP) Net Cash Flow (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Net Cash Flow for 4 consecutive years, with $25.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 3080.35% year-over-year to $25.4 million; the TTM figure through Mar 2026 stood at $20.5 million (up 222.74% YoY), while the FY2025 annual figure was -$4.2 million, up 68.82% from the prior year.
- Net Cash Flow improved to $25.4 million in Q1 2026 per RAPP's latest filing, from -$198.7 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $196.3 million in Q3 2025 and bottomed at -$198.7 million in Q4 2025.
- Historically, Net Cash Flow has averaged -$124272.7 across 4 years, with a median of $4.1 million in 2024.
- Annual changes were most pronounced in 2025 — Net Cash Flow plunged 1236.09% — and 2026, when it soared 3080.35%.
- Rapport Therapeutics' Net Cash Flow stood at -$89.2 million in 2023, then soared by 119.62% to $17.5 million in 2024, then slumped by 1236.09% to -$198.7 million in 2025, then surged by 112.79% to $25.4 million in 2026.
- Business Quant data shows RAPP's Net Cash Flow at $25.4 million in Q1 2026, -$198.7 million in Q4 2025, and $196.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | -14.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.44 Mn |
| Jun 30, 2026 | -14.44 Mn |
| Mar 31, 2026 | 25.41 Mn |
| Mar 31, 2026 | 25.41 Mn |
| Dec 31, 2025 | -198.71 Mn |
| Dec 31, 2025 | -198.71 Mn |
| Sep 30, 2025 | 196.29 Mn |
| Sep 30, 2025 | 196.29 Mn |
| Jun 30, 2025 | -2.54 Mn |
| Jun 30, 2025 | -2.54 Mn |
| Mar 31, 2025 | 799,000.00 |
| Mar 31, 2025 | 799,000.00 |
| Dec 31, 2024 | 17.49 Mn |
| Dec 31, 2024 | 17.49 Mn |
| Sep 30, 2024 | -70.85 Mn |
| Sep 30, 2024 | -70.85 Mn |
| Jun 30, 2024 | 35.90 Mn |
| Jun 30, 2024 | 35.90 Mn |
| Mar 31, 2024 | 4.12 Mn |
| Mar 31, 2024 | 4.12 Mn |